TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29231540
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (acupuncture at GV and Jiaji combined with rehabilitation training)
Study: 23132445
Drug: Omega-3 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 oral nutritional supplements (TheraTears Nutrition for Dry Eyes)
Study: 14620923
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive agents (control)
Study: 10906645
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid gel, pH 3.52, applied once daily for 7 days and then twice daily for 2 weeks
Study: 10906645
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, pH 5.75
Study: 10906645
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid gel, pH 3.52
Study: 1427582
Drug: Amikacin once
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin once daily plus metronidazole
Study: 1427582
Drug: Amikacin twice
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Amikacin twice daily plus metronidazole
Study: 6565300
Drug: Drug information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug information only
Study: 6565300
Drug: Combined drug
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined drug and SEMT information
Study: 27757142
Drug: Therapeutic educational
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic educational program in oral health (TEPOH)
Study: 19099860
Drug: Midodrine hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine hydrochloride and oral rehydration salt treatment
Study: 19099860
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salt treatment only
Study: 16317760
Drug: IV EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV EPO 600 IU/kg (max dose 40,000 IU) or placebo once weekly for 16 weeks, increased to 900 IU/kg (max dose 60,000 IU) if no response by week 3 or 4
Study: 15048616
Drug: Moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150 mg b.i.d. for 14 days
Study: 7957792
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (200,000 IU, single oral dose)
Study: 23951825
Drug: Elonza (generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elonza (generic product of sildenafil) 100 mg taken as needed
Study: 10636375
Drug: Maternal oral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal oral zidovudine
Study: 7488485
Drug: Thiopentone 6
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 6 mg kg‐1
Study: 1827966
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg oral ondansetron
Study: 7302464
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of sodium aurothiomalate weekly
Study: 7302464
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of sodium aurothiomalate weekly
Study: 27698559
Drug: TURP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURP plus tamsulosin hydrochloride 0.2 mg (TAM)
Study: 27698559
Drug: TURP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURP plus tamsulosin hydrochloride 0.2 mg (TAM) plus solifenacin succinate 5 mg (SOL)
Study: 16337504
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day for 12 months
Study: 16337504
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg/day for 3 months
Study: 14620649
Drug: Nicotine patch/bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch/bupropion group
Study: 14620649
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch group
Study: 10354218
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg of TNF-alpha plus 1 mg kg-1 melphalan (IHPTM group)
Study: 10354218
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg kg-1 melphalan (IHPM group)
Study: 8877260
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (nisoldipine)
Study: 16327016
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (enalapril)
Study: 1757024
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cefamandol administered intraocularly at the end of the operation
Study: 1757024
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intraocularly at the end of the operation
Study: 7113575
Drug: Chlorpropamide administration
Normalized name: Chlorpropamide
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide administration (CPAF test)
Study: 7113575
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration instead of chlorpropamide
Study: 30547820
Drug: Low-dose stavudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose stavudine (20 mg twice daily)
Study: 30547820
Drug: Tenofovir in
Normalized name: Product containing tenofovir in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir in combination with efavirenz and lamivudine
Study: 30547820
Drug: Low-dose stavudine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose stavudine
Study: 20394471
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg QD for 3 weeks
Study: 20394471
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg QD for 2 weeks
Study: 20394471
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg QD for 4 weeks
Study: 2327823
Drug: AIH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIH with semen mixed with kallikrein (K, 5 IE/ml semen, n = 45)
Study: 3433917
Drug: RA 27/3
Normalized name: Rubivirus rubella virus Wistar RA 27/3 whole
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA 27/3 rubella vaccine
Study: 7017582
Drug: Measles-mumps-rubella (RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella (RA 27/3) vaccine
Study: 7017582
Drug: Combination vaccine
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccine incorporating HPV-77:DE-5 rubella
Study: 7017582
Drug: Measles-mumps-rubella vaccines
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles-mumps-rubella vaccines
Study: 20182421
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of tacrolimus
Study: 9052903
Drug: Xanomeline (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline (oral formulation)
Study: 9052903
Drug: Xanomeline (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanomeline (first dose)
Study: 8306902
Drug: Hydroflumethiazide (HFM)
Normalized name: Hydroflumethiazide
DrugBank: Hydroflumethiazide (DB00774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroflumethiazide (HFM) 50mg daily
Study: 8306902
Drug: Propranolol 80mg
Normalized name: HCTZ 25/PROPRANOLOL 80MG TAB
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 80mg daily
Study: 8306902
Drug: Propranolol 160mg
Normalized name: HCTZ 50/PROPRANOLOL 160MG SA CAP
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 160mg daily (after 4 weeks)
Study: 30893577
Drug: MRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA therapy (intravenous bolus of potassium canrenoate followed by oral spironolactone for 3 months)
Study: 30893577
Drug: MRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRA therapy
Study: 29183291
Drug: Hockey Fans
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hockey Fans in Training (Hockey FIT) program, 90-minute weekly sessions for 12 weeks followed by a 40-week minimally-supported phase.
Study: 26085531
Drug: Twenty-four-hour group
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-four-hour group (received perioperative antibiotics for twenty-four hours)
Study: 26085531
Drug: Drain-duration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drain-duration group (received antibiotics for the duration that the drain was in place)
Study: 15218999
Drug: BA+ICS (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA+ICS (0.2 mg salbutamol t.i.d. and 0.2 mg budesonide t.i.d.)
Study: 10899363
Drug: d-amphetamine (AMPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (AMPH; 15 mg oral)
Study: 9270499
Drug: Newer antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer antimicrobial agents (third- and fourth-generation cephalosporins, β-lactam, β-lactamase inhibitor combination agents, monobactams, carbapenems, macrolides, fluoroquinolones)
Study: 9270499
Drug: Older antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older antimicrobial agents
Study: 3089942
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin V‐K (100,000 U/kg/day every 6 h)
Study: 29932415
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (2 mL)
Study: 29932415
Drug: Procaine injection
Normalized name: Procaine Injection Oil
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procaine injection
Study: 26149510
Drug: ADHD medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD medications (stimulant or nonstimulant)
Study: 26149510
Drug: No ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ADHD medications (control group)
Study: 23086673
Drug: Conventional hypervolemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hypervolemic therapy (HT)
Study: 16575034
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg x kg(‐1))
Study: 16575034
Drug: Aminophylline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (3 mg.kg(‐1))
Study: 15198411
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg plus dexamethasone 8 mg
Study: 3052571
Drug: CSII and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII and MI (intensified treatment)
Study: 31122650
Drug: Pre-learning propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-learning propranolol (40 mg)
Study: 31122650
Drug: Post-learning propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-learning propranolol (40 mg)
Study: 31122650
Drug: Pre-encoding propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-encoding propranolol (40 mg) in women
Study: 28207655
Drug: Standard-dose C-arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose C-arm fluoroscopy
Study: 23624059
Drug: Oral source
Normalized name: AMYLOPECTIN, UNSPECIFIED SOURCE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral source of glucose (juice) during reconsolidation
Study: 19023522
Drug: Heparin used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin used in 26% of patients
Study: 7594429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and doxazosin (study A)
Study: 7594429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and enalapril (study B)
Study: 2253658
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg injected intravenously
Study: 7011279
Drug: Cimetidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1.0 g/day initially, increased to 1.6 g/day if less than 50% reduction in ulcer size)
Study: 7011279
Drug: Cimetidine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (600 mg/day)
Study: 7011279
Drug: Cimetidine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (after stopping maintenance treatment)
Study: 30924166
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg intravenously
Study: 28347540
Drug: Sivelestat administered
Normalized name: Sivelestat
DrugBank: Sivelestat (DB12863)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sivelestat administered perioperatively for 5 days
Study: 28347540
Drug: No medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medications administered (Control group)
Study: 25864870
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D + omega-3 PUFA (30 µg vitamin D3, 3000 mg eicosapentaenoic acid, 3000 mg docosahexaenoic acid)
Study: 21156702
Drug: 5-fluorouracil and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil and low-molecular-weight heparin
Study: 19717506
Drug: Low-frequency sound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency sound wave therapy, 3-5 times a week for 30 minutes per session over 6 months
Study: 19717506
Drug: Low-frequency sound
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency sound wave therapy
Study: 17451140
Drug: Antihypertensive drugs,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs, specifically blockers of the renin-angiotensin axis
Study: 8313326
Drug: Conservative surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative surgery plus radiation therapy
Study: 3046826
Drug: Piroxicam, 20
Normalized name: Piroxicam, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam, 20 mg per day
Study: 3046826
Drug: Naproxen, 750
Normalized name: Naproxen, 750 mg (as sodium) oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 750 mg per day
Study: 29687457
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT), 10-session manualized intervention
Study: 23692516
Drug: ICA-105665 100
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-105665 100 mg
Study: 23692516
Drug: ICA-105665 400
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-105665 400 mg
Study: 23692516
Drug: ICA-105665 500
Normalized name: ICA-105665
DrugBank: ICA-105665 (DB06089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICA-105665 500 mg
Study: 20697044
Drug: 450 or
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 or 900 mg of idebenone per day (n = 22)
Study: 20697044
Drug: 1350 or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1350 or 2250 mg of idebenone per day (n = 24)
Study: 10807098
Drug: Hyaluronan injections
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan injections
Study: 9387366
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Zusanli (ST 36) and Neiguan (PC 6) combined with epidural anesthesia of small dosage (group A)
Study: 9387366
Drug: Simple epidural
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple epidural anesthesia of small dosage (group B)
Study: 15374380
Drug: Amantadine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (200 mg for 1 h)
Study: 3881014
Drug: Cimetidine 1800
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1800 mg/day
Study: 3881014
Drug: Sucralfate 8
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate 8 g/day
Study: 30585829
Drug: Platelet decrease
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet decrease following renal replacement therapy initiation
Study: 26197029
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of terbutaline (TER)
Study: 17227746
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (optimal medication identified after screening phase)
Study: 17227746
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (optimal medication identified)
Study: 15176988
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg daily plus elemental calcium 500 mg daily
Study: 15176988
Drug: Calcium 500
Normalized name: Calcium 500+D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 500 mg daily alone
Study: 9839093
Drug: Acarbose (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (25-100 mg t.i.d.)
Study: 2543048
Drug: New less
Approvals — FDA: no, EMA: no, PMDA: no
Description: New less toxic treatment
Study: 24075291
Drug: Lawton‐Brady activities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lawton‐Brady activities of daily living (ADL) scale
Study: 21169060
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab with first-cycle rash
Study: 21169060
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus cetuximab without first-cycle rash
Study: 11107075
Drug: PTFE Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE Patch Closure
Study: 11107075
Drug: PTFE Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE Patch Closure and Vein Patch Closure (VPC)
Study: 2989349
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 10 mg orally)
Study: 2989349
Drug: Enalapril (long-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (long-term treatment)
Study: 20974575
Drug: Raltegravir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 800 mg once daily
Study: 20974575
Drug: Raltegravir twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir twice daily for 3 months then once daily
Study: 17017631
Drug: Liquid whitening
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid whitening gel (5.9% hydrogen peroxide, twice a day for 15 minutes)
Study: 17017631
Drug: Sodium chlorite‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chlorite‐based whitening gel applied in a tray system (10 minutes twice a day)
Study: 2860739
Drug: STA‐MCA bypass
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA‐MCA bypass in addition to medical therapy (daily aspirin and aggressive hypertension control)
Study: 2860739
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment alone (daily aspirin and aggressive hypertension control)
Study: 28625036
Drug: Sago worm
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sago worm inclusive diet (100 g per day for 45 days)
Study: 26309676
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of deep-breathing exercises and oxygen inhalation
Study: 23648640
Drug: Disulfiram (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (0, 250, 375, or 500 mg/d)
Study: 16492207
Drug: Pioglitazone (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (initial dose 15 mg/day, increased to 30 mg/day)
Study: 16492207
Drug: Voglibose (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (initial dose 0.6 mg/day, increased to 0.9 mg/day)
Study: 15611421
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy group
Study: 9294378
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone for 14 months
Study: 9294378
Drug: Psychosocial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial treatment alone for 14 months
Study: 9294378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medication and psychosocial treatment for 14 months
Study: 8403175
Drug: Regularly dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regularly dosed oral morphine (20 mg every four hours)
Study: 8403175
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (equivalent dose every four hours)
Study: 31472099
Drug: Emollient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient treatment
Study: 27716604
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg, oral, twice a day for 4 weeks)
Study: 27716604
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo, oral, twice a day for 4 weeks)
Study: 22555328
Drug: Cefaclor, 50
Normalized name: Cefaclor, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor, 50 mg/kg/day, administered twice daily for five days
Study: 22555328
Drug: Amoxicillin/clavulanate, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate, 40 mg/kg/day administered twice daily for 10 days